RIL
PCRX icon

Rothschild Investment LLC’s Pacira BioSciences PCRX Stock Holding History

Rothschild Investment LLC’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.04K Buy
120
+5
+4% +$118 ﹤0.01% 2560
2026
Q1 		$2.6K Buy
115
+10
+10% +$222 ﹤0.01% 2425
2025
Q4 		$2.72K Hold
105
– – ﹤0.01% 2210
2025
Q3 		$2.71K Buy
105
+5
+5% +$123 ﹤0.01% 2034
2025
Q2 		$2.39K Hold
100
– – ﹤0.01% 1947
2025
Q1 		$2.48K Buy
100
+10
+11% +$239 ﹤0.01% 1761
2024
Q4 		$1.7K Buy
90
+70
+350% +$1.23K ﹤0.01% 1906
2024
Q3 		$301 Sell
20
-72,972
-100% -$1.25M ﹤0.01% 2609
2024
Q2 		$2.09M Buy
72,992
+33,098
+83% +$942K 0.15% 132
2024
Q1 		$1.17M Buy
39,894
+39,273
+6,324% +$1.21M 0.08% 210
2023
Q4 		$21K Sell
621
-39,463
-98% -$1.15M ﹤0.01% 851
2023
Q3 		$1.23M Sell
40,084
-243
-0.6% -$8.76K 0.1% 181
2023
Q2 		$1.61M Buy
40,327
+31,033
+334% +$1.28M 0.13% 145
2023
Q1 		$379K Hold
9,294
– – 0.03% 335
2022
Q4 		$359K Buy
9,294
+63
+0.7% +$3.06K 0.03% 338
2022
Q3 		$491K Hold
9,231
– – 0.05% 281
2022
Q2 		$539K Buy
9,231
+174
+2% +$11.4K 0.05% 279
2022
Q1 		$692K Buy
9,057
+134
+2% +$8.93K 0.05% 269
2021
Q4 		$537K Hold
8,923
– – 0.04% 316
2021
Q3 		$500K Sell
8,923
-10
-0.1% -$576 0.04% 311
2021
Q2 		$542K Sell
8,933
-248
-3% -$15.7K 0.04% 312
2021
Q1 		$643K Buy
9,181
+991
+12% +$70.8K 0.06% 273
2020
Q4 		$490K Sell
8,190
-808
-9% -$47.3K 0.05% 289
2020
Q3 		$541K Buy
8,998
+939
+12% +$54.6K 0.06% 253
2020
Q2 		$423K Sell
8,059
-17,754
-69% -$742K 0.05% 270
2020
Q1 		$866K Buy
25,813
+19,204
+291% +$798K 0.11% 178
2019
Q4 		$299K Buy
+6,609
New +$281K 0.03% 360

Other funds holding PCRX

GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BS
Banco Santander Madrid, Spain $16.1B AUM 35.02% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Rothschild Investment LLC's PCRX Position: Q2 2026 in Review

Rothschild Investment LLC increased its Pacira BioSciences (PCRX) stake by 4.3% in Q2 2026, buying an estimated $118 and bringing the position to 120 shares worth $3.04K. The position accounts for ﹤0.01% of the portfolio, ranked #2560.

Rothschild Investment LLC first reported a position in PCRX in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.09M in Q2 2024. 79 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Rothschild Investment LLC held 120 shares of Pacira BioSciences worth $3.04K as of Q2 2026.
  • Rothschild Investment LLC bought 5 Pacira BioSciences shares in Q2 2026, an estimated $118.
  • Pacira BioSciences made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #2560 holding.
  • Rothschild Investment LLC first reported a position in Pacira BioSciences in Q4 2019 and has held it in 27 quarters since.
  • Rothschild Investment LLC's Pacira BioSciences position peaked at $2.09M in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.